Nidan

Query execution is a challenging task in the big data environment, as the execution might not always be easy to handle. Some big data frameworks provide efficient ways to execute queries with the most optimized approach. These queries are based on the various operators used with Apache Pig and Apache Hive. Since these are used for performing query execution inside the Hadoop ecosystem, which contains large volumes of data in a distributed environment, both are built on top of the Map Reduce framework for query processing. Consequently, Apache Hive focuses on SQL-like queries, while Apache Pig uses a programmatic approach for executing Pig Latin script. In this research work, we propose a query execution-based approach using various operators of Pig and Hive. We wrote simple and complex queries based on an IoT dataset and analyzed the performance in terms of execution time for both components. The comparative analysis shows that simple and complex queries can be efficiently handled using the Apache Hadoop ecosystem. The hive performed better than the pig for various types of queries, while system resources differ based on types of queries.

BackgroundDue to the progressive decline in β-cell function, it is often necessary to utilize multiple agents with complementary mechanisms of action to address various facets and achieve glycemic control. Thus, this study aimed to evaluate the efficacy and safety of a fixed-dose combination (FDC) of metformin/sitagliptin/pioglitazone (MSP) therapy vs. metformin/sitagliptin (MS) in type 2 diabetes mellitus (T2DM).MethodsIn this phase 3, multicenter, double-blind study, patients with T2DM who exhibited inadequate glycemic control with HbA1c of 8.0–11.0% while taking ≥1500 mg/day metformin for at least 6 weeks were randomized to receive either FDC of MSP (1000/100/15 mg) or MS (1000/100 mg) per day for 24 weeks. The primary outcome measure was the change in HbA1c, and secondary outcomes included changes in fasting plasma glucose (FPG), postprandial plasma glucose (PPG), and body weight from baseline to 24 weeks along with safety and tolerability.ResultsAmong the 236 patients randomized, 207 (87.71%) successfully completed the study. All baseline characteristics were comparable between the FDC of MSP and MS groups. There was a subsequent significant reduction of HbA1c in FDC of MSP (− 1.64) vs. MS (− 1.32); between groups was [− 0.32% (95% CI, − 0.59, − 0.05)], P = 0.0208. Similar reductions were found in FPG [− 13.2 mg/dL (95% CI, − 22.86, − 3.71)], P = 0.0068, and PPG [− 20.83 mg/dL (95% CI, − 34.11, − 7.55)], P = 0.0023. There were no significant changes in body weight. A total of 27 adverse effects (AEs) and one severe AE were reported, none of which were related to the study drug.ConclusionThe FDC of MSP demonstrated significant efficacy in managing glycemic indices and could serve as a valuable tool for physicians in the management of Indian patients with T2DM.Trial registrationClinical Trials Registry of India, CTRI/2021/10/037461.

IntroductionObesity has become a rising health concern in Pakistan. Several primary measures, such as dietary restrictions and regular exercise, are taken to limit the severe consequences of obesity. Still, such measures alone have been proven to be often short term and therefore, inadequate. In this study, we will evaluate the role of pharmacological management via orlistat in obesity.Methods and MaterialsA total of 120 patients were enrolled in this study and were divided randomly into two groups (drug arm and placebo arm) of 60 patients each. A standard dose of 120 mg capsules of orlistat given three times a day was administered to the participants of the drug arm group. A placebo was given to the participants in the second group. Baseline investigations were conducted on day 0 of the study, and follow-up visits were planned to take place in week 24 for all participants. Any side effects or adverse events were inquired about and documented in these visits.ResultsIn the orlistat arm, we noted a significant reduction in both body mass index (BMI) (0.04) and waist circumference (0.04). Reduction in weight was more in the orlistat arm than in the placebo arm. However, it is non-significant when compared between day 0 and week 24. Adverse events, such as oily spotting (31.91%), flatus with discharge (27.65%), faecal urgency (25.53%) and fatty stool (35.553%), were significantly higher in the orlistat arm.ConclusionOrlistat has shown positive results in reducing weight, BMI and waist circumference; however, patients should be counselled about potential side effects caused by the mechanism of action of Orlistat.

Grahani Roga is a disease of Annavaha Srotas caused due to the production of Ama and Mandagni. Elimination of vidagdha paka or apakwa anna through the anal canal is known as Grahani Roga. Acharya Charak has mentioned that Mandagni causes improper digestion of ingested food, which moves either in Urdhwa or Adho-Marga. When it goes into Adho-marga, then it leads to Grahani Gada. Acharya Sushrut has mentioned that, patients of Atisara, during the stage of Agnimandya, if take incompatible diet, may lead to Grahani Roga. So Agni plays an important role for producing this disease. Muhurvaddha muhurdrava mala pravriti (altered bowel habit), Shlesma mala pravriti (mucous in stool) are the main symptoms of this disease. By considering the above facts the trial drug an indigenous herbal compound which contains Bilwa, Chavya, Chitraka and Sunthi in equal quantity was selected to reduce the pathogenesis of this disease. Most of the ingredient of this formulation possesses Ama Pachana, Agni Deepana and Grahi qualities. A total number of 45 patients were selected and divided into two groups. Simple random sampling methods were used in this study. In the study group 30 patients were given with the trial drug and in the other group patients were given with placebo drug. Mild to moderate improvements in symptoms of Grahani found in trial group. In placebo group patients also have shown certain improvement in the symptom of Tikta Amla Udgara and Mukha vairasya. Trial drug has shown more effective in bowel habit of Grahani patients.

Mukha (mouth) is one of the important parts of body and it is exposed to various risk factors due to the bad habits like tobacco chewing and smoking etc. Mukhapaka is pathological condition related to Mukha which occurs due to the simple cut, eating hot food items, unhygienic cleaning, vitamins deficiencies and adverse reaction of antibiotics. Lalasrava, Glani, Dugdha Dwesha, Vyatha and Nasa Shwasa etc. are general symptoms of Mukhapaka. As per ayurveda Mukha Rogas is Pittaja Nanatmaja and Rakta Pradoshaja Vikara and around 20% of population is suffering with this problem. Ayurveda described various treatment modalities for the management of Mukhapaka; Ashwattha Choorna Lepa is one of them, present article established efficacy of Ashwattha Choorna Lepa in Mukhapaka. The study concluded that Lepan-Karma with ayurveda formulation Ashwattha Choorna offers beneficial effects in mouth ulcer.

The development of medical system in India witnessed by all common era and the seeding of ancient ayurveda science starts from early development of civilization. The emergence of traditional medical system involves description of religious medicine practiced from the Vedic period in India. The initial development phase of natural medical system later on shaped as Ayurveda which encompasses various logical and rational concept related to the health and well being. The theory and practice of ayurveda mainly based on experimental conclusion of vaidya and ancient practitioners. Similarly the historical perspective of infectious diseases is very vast as per the modern and traditional science. Ayurveda researchers and practitioners described various types of infectious diseases time by time and also offered textual evidences of pathogenic organisms. This article presented historical review on infectious diseases as per ayurveda in a view to explore ayurveda perspective of such diseases and their causative organisms. Keywords: Ayurveda, Sankramak disease, infections, microbes, pathogens, Vedic period.Â

This article presented unique approach for selecting appropriate partner for love, business and game etc. since choosing a right person is complicated and it is very difficult when partners are unknown to each other. The article described simple and unique approach to find out right life partner considering his/her prakriti; likes, dislike, temperament and aptitude, etc.

Introduction:For the diagnosis of various aspects of disease and diseased person, several methods have been described in the Ayurvedic texts. These can be broadly classified into Roga and Rogi Pariksha. Several methods of Roga-Rogi Pariksha such as Ashtasthana, Dashavidha, Dvadashavidha Pariksha are described. Mutra Pariksha was the main laboratory investigative tools in the past and it is included under Ashtasthana, Pariksha. There is no direct description of methodology to ascertain the prognosis of cancer in the Ayurvedic classics. Taila Bindu Pariksha, which is a part of Mutra Pariksha helps in assessing the prognosis of a disease. Eastern Cooperative Oncology Group (ECOG) had developed the scale to ascertain prognosis of cancer in 1955. These ECOG performance scale gives doctors and research scholars a scale with which they can quickly assess the functional capacity of a patient and the progress of disease.Aim:To evaluate the prognosis of cancer by Taila Bindu Pariksha and compare the results with ECOG scale.Materials and Methods:A pilot study was undertaken on a single group of 20 cancer patients which are advised radio or chemotherapy for further management. The urine samples collected from the patients were subjected to Taila Bindu Pariksha. The ECOG scale was also assessed and compared with shape and direction of spread.Result:In majority of the patients, the correlation was found statistically highly significant.Conclusion:Taila Bindu Pariksha may be used as an alternative method to ascertain the prognosis of the cancer patients.